Zydus Lifesciences Ltd (ZYDUSLIFE) Q2FY27 Management Mirror - Sep-2026 Qtr
Sep'26 Qtr EBITDA Margin Reported at 24.0%, Meeting the 24%+ FY27 Guidance Initiated in Mar'26 Qtr
In Sep'26 Qtr, the company reported a consolidated EBITDA margin of 24.0% alongside consolidated EBITDA of Rs 18,945 million. This met the full-year FY27 EBITDA margin guidance of in excess of 24% initially guided in the Mar'26 Qtr concall and reaffirmed in the Jun'26 Qtr. Looking ahead, management reaffirmed its guidance of delivering a 24% plus EBITDA margin for the full year FY27, noting that the second half is expected to maintain similar margin levels as increased commercial launch expenditures counterbalance gross profit additions.
3 more themes on the ELITE plan.